Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ASCB 2016 Show Preview: Following the arc of scientific discovery
November 2016
by Jeffrey Bouley  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

American Society for Cell Biology (ASCB)
56th Annual Meeting
Moscone Center, San Francisco
December 3-7, 2016
 
Following the arc of scientific discovery
 
American Society for Cell Biology 56th annual meeting headed for San Francisco
 
From Dec. 3-7 this year, the Moscone Center in San Francisco will be the very brief and temporary home of the American Society for Cell Biology (ASCB) as it holds its 56th annual meeting, otherwise known as ASCB 2016. As with any annual meeting, there are the routine things like exhibits, educational sessions, special interest subgroup meetings and social events, not to mention the “usual suspects” with respect to ASCB meeting attendees, which run the wide range of people involved in such areas as cell biology, computational biology, molecular biology, CRISPR/Cas9 RNA sequencing, image analysis, neuroscience, cancer, Big Data science, biophysics, super resolution microscopy, immunology, genetics, developmental biology, translational research, science education and biotech.
 
ASCB Executive Director Dr. Erika C. Shugart tells DDNews that part of the goal this year was “giving our attendees more of what they like best—the chance to network and to learn about the latest science. We have more member-organized subgroup sessions and we have expanded the number of minisymposia and microsymposia speaking slots.”
 
But she also noted what she calls an “exciting new addition” this year for ASCB 2016.
 
“We will hold the inaugural Doorstep Meeting on the Cell Biology of Cancer. This exciting one-day meeting will bring together cancer biologist and cell biologists to explore the intersections of their sciences. As Alan Ashworth, a co-organizer, notes: ‘We think we’re getting to know how to treat cancer, but the reality is that we still know very little about the cellular underpinnings of cancer.’”
 
The Doorstep Meeting will be ASCB’s first-ever full-day symposium. It is designed to familiarize the cell biology community with advances and opportunities in the cancer field and will be held on Saturday—the first day of the annual meeting, hence the name “Doorstep Meeting.” The event is jointly organized by ASCB and the National Cancer Institute, with funding from Howard Hughes Medical Institute. The program is organized by Alan Ashworth of the University of California, San Francisco, and Ira Mellman of Genentech Inc., will facilitate networking and discussion.
 
The meeting will cover a broad range of topics of current relevance to cancer to help researchers in cell biology develop a core knowledge of the disease and to identify areas of opportunity in which basic cell biological research promises to profoundly contribute to cancer prevention, treatment and cure. Cancer treatment is becoming increasingly specialized, with new drugs targeting specific genes and phenotypes of cancer subtypes, ASCB notes of the program. However, a cell biology approach to understanding cancer could identify common principles among cancer cells to allow a more pan-cancer approach to treatment.
 
The program will cover 11 topics in 25-minute talks by experts in the field, with 10 minutes for questions and answers, with the topics as follows:
  • The Cell Biology of Cancer Immunotherapy
  • DNA Repair and Cancer Pathogenesis and Therapy
  • Forcing Form and Function
  • Stromal-Immune Interactions in Cancer
  • Macrophages Are a Cellular Toolbox That Promotes Tumor Progression and Metastasis
  • SWI/SNF (BAF) Complex Mutations in Cancer
  • Cancer Therapy Resistance: A Cell Biologist’s Perspective
  • Lymphatic Vessels in Inflammation and Cancer: New Insights into Immune Regulation
  • The Autophagy Adaptor p62/SQSTM1 Is a Key Mediator of Liver Cancer Development
  • The Regulation of Metastasis
  • Toward a Tumor Cell Atlas: Dissecting the Tumor Ecosystem with Single Cell Genomics
As Shugart notes, this year’s annual meeting, which is operating under a theme of “Following the arc of scientific discovery,” will be very focused on using disease to illuminate basic cell biology.
 
And while there are great deal of other educational and informational programming during the event aside from the Doorstep Meeting to cover that approach and theme, Shugart notes that DDNews readers attending the event might be particularly interested in ASCB 2016 workshops on imaging the cell in the 21st century, with a look at challenges and opportunities in fluorescence microscopy; cryo-electron microscopy (more commonly known as cryo-EM), with a focus on what the technology can do now and how you can get started; and leveraging CRISPR for precision biology.
 
Several symposia should also be of interest to DDNews readers, she says, citing Disease Informing Cell Biology, Logic of Signaling and Mitochondria and Cancer Cell Biology as three good examples.
 
“As you can see from the sessions, we have a lot to offer people who are interested in the future of medicine and what the most cutting-edge science might offer as the next targets and potential cures,” Shugart says. She also highlighted the ASCB 2016 keynote speaker, Dr. Richard P. Lifton of The Rockefeller University, who will speak on “Genes, Genomes and the Future of Medicine.” More on that keynote in another article later in this section.
 
Looking toward next year, when the annual meeting will be in Philadelphia (from Dec. 2-6, 2017), Shugart says ASCB will partner with the European Molecular Biology Organization (EMBO) for a joint ASCB/EMBO meeting.
 
Says Shugart: “As our President-elect Pietro De Camilli observes, ‘Science is an international endeavor. The ASCB has become a beacon for this, not only in America but in the world. Many members of EMBO, one of the strongest European scientific societies, are already ASCB members. The joint meeting will acknowledge and consolidate our partnership.’ We will also offer a Doorstep Meeting [in 2017] that brings together cell biology and neuroscience. This will be an opportunity for attendees to explore the intersection of two hot areas of science.”

ASCB 2016 Keynote: Rick Lifton takes exome sequencing beyond mendelian genetics
 
By John Fleischman of ASCB
 
Rick Lifton was moving house. After 23 years in New Haven at Yale, Lifton was packing up last July for Manhattan where on Sept. 1, he would become the 11th president of the Rockefeller University. The job comes with an on-campus residence, a spectacular free-standing house overlooking New York’s East River that is also used to host official gatherings. “I haven’t counted the bedrooms yet. I think it’s five,” Lifton reported.
 
Lifton will have firmer ideas about his new house and new job by the time he arrives in San Francisco on Dec. 3 to give the keynote address for ASCB 2016. It won’t be Lifton’s first time at ASCB, he said. He gave a keynote talk at ASCB in 1998. At that time, Lifton was noted for his genetic studies of hypertension, identifying rare mutations that drive either extraordinarily high or low blood pressure and tracing all to mutated genes that severely misregulate renal salt absorption. “But it’s been a long time,” said Lifton, “and a fair amount has changed since then.” That is an understatement on the order of saying that Lifton lives in New York City.
 
Exome sequencing is what changed everything. Lifton was one of the pioneers of a new kind of forensic genetics that combines emerging genomic sequencing technologies with a different sampling approach focused exclusively on the exons, the roughly 180,000 protein-coding genes that make up 1 percent of the human genome but are thought to harbor the vast majority of the mutations with large effects in human disease. With exome sequencing, the Lifton lab has pried open the hitherto hidden genetic underpinnings of a startling range of human conditions from tumors that produce endocrine hormones to idiopathic pulmonary fibrosis to congenital heart disease.
 
Following the initial sequencing of the human genome in 2001, it was clear that re-sequencing the genome by massively parallel sequencing was possible, but extremely expensive. Given that the vast majority of mutations with large phenotypic effect that had been mapped in an unbiased fashion and then identified had proved to be attributable to effects on protein-coding regions and flanking intron-exon boundaries, selectively sequencing the 1 percent of the genome comprising coding sequence seemed an attractive approach for Mendelian discovery.
 
Lifton had developed methods for physically purifying mRNAs by hybridization to cloned DNA as a graduate student in the 1970s. But the idea of doing the analogous simultaneous selection of DNA of all exons of the human genome nonetheless seemed audacious, recalled Lifton, who, before his new Rockefeller post, was chair of genetics at Yale Medical School and a Howard Hughes Medical Institute investigator. The idea of exome sequencing was in the zeitgeist of the time, and a number of academic labs and companies worked on the idea.
 
Lifton is careful to point out that others, especially Jay Shendure at the University of Washington, also developed robust methods for exome capture. Lifton and colleagues developed an analogous capture approach working with scientists at Nimblegen, iteratively testing and modifying protocols to come up with a robust protocol for production and data analysis. They eventually were satisfied that they could identify homozygous and heterozygous sequence variants with high sensitivity and specificity. As an initial “test drive” of the technology, in 2009 they pulled off the hat trick in genetic medicine—the first definitive diagnosis of a human genetic disorder by genomic or exomic sequencing.
 
An example of a disease featuring gene-environment interaction from recent work is pulmonary fibrosis, in which his group, collaborating with Christine Garcia’s lab at University of Texas Southwestern, discovered mutations in the genes PARN and RTEL1 that cause disease in conjunction with inhaled environmental exposures. “You may be fine if you’re never exposed to an environmental co-factor,” Lifton explained. Susceptibility to certain infections could be another example. “You may be fine with a mutation in the interferon response pathway unless exposed to a Neisseria that causes meningitis, in which case your ability to fight it off is drastically impaired.”
 
All of this [and other work in the area], Lifton believes, points to a clear path forward to answer the truly big question revealed by exome sequencing: “What is the consequence of a mutation in every gene in the human genome?”
 
Getting there, said Lifton, is not going to be easy and will require a closer interweaving of labs working in genetics, biochemistry and cell biology to explain the mechanism. “What remains to be done in human genetics? The answer is practically everything.”
-------------------------
This article was edited and shortened from the Sept. 12 article “ASCB 2016 Keynote Speaker: Rick Lifton Takes Exome Sequencing Beyond Mendelian Genetics” that appeared on the ASCB website and was written by John Fleischman, ASCB’s senior science writer.
 
Biotech Mini Course
 
The ASCB and Keck Graduate Institute are partnering to offer a one-day course for graduate students and postdocs on Dec. 2, 2016, the day before the ASCB Annual Meeting. The course will help basic scientists become more competitive for jobs in biotech, pharma and industry.
 
Designed for graduate students and postdocs, the course will introduce students to bioscience commercialization processes through case study analysis and group problem-solving exercises.
 
An “Introduction to Bioscience Business” morning session from 8 a.m. to noon will introduce students to bioscience industry dynamics and commercialization processes. The session will be highly interactive, combining short introductory lectures with discussions of bioscience industry cases.
 
Noon to 2 p.m. will bring a networking lunch with representatives from local biotech companies, followed from 2 p.m. to 5 p.m. by “The Business of Science—Combining Your Scientific, Business, and Social Skills to Make You ‘Business-Ready’ and Competitive for a Professional Career.”
 
Among the areas to be covered:
  • What can I be with a Ph.D.? Learn the different career paths available and the kinds of institutions that value doctorate holders.
  • Developing your career plan. Apply “What you can be with a Ph.D.” to reevaluate career choices and learn to build and leverage your network to identify critical skills.
  • Teams will research job descriptions for real positions you desire to identify critical technical business and social skills and relate those to your own accomplishments.
  • Develop a targeted resume that matches your technical business and social skill accomplishments to job-specific requirements.
  • Preparing for interviews. Research your company, your job and the interviewers. Prepare for the tough questions. Learn to shift from “expert” to “learner” and apply effective communications
Presenters are Randall Ribaudo and Larry Petcovic, co-founders of SciPhD, a company that specializes in helping scientists prepare for professional careers.
 
ASCB 2016 symposia
 
Symposium 1: Mechanical Forces in Cell Biology
Sunday, Dec. 4, 8 a.m.
  • Rapid cell migration through dense tissues—it is easier for a camel to go through the eye of a needle
  • Under pressure: epithelial cell population control
  • Forcing Form and Function
Symposium 2: Organelle Organization
Sunday, Dec. 4, 9:45 a.m.
  • The behavior of mitochondria
  • The Cell Biology of Lipid Storage
Symposium 3: Disease Informing Cell Biology
Monday, Dec. 5, 8 a.m.
  • Cell biological and genetic basis of neurodevelopmental disease
  • Mitochondrial parts, pathways, and pathogenesis
Symposium 4: Quality Control
Monday, Dec. 5, 9:15 a.m.
  • Selective inhibition of a phosphatase to correct protein quality control failures and treat neurodegenerative diseases
  • Stressed out: A novel approach to cancer immunotherapy
  • Mechanisms of nascent protein quality control in the cytosol
Symposium 5: Cellular Communities
Tuesday, Dec. 6, 8 a.m.
  • Quorum sensing and its control
  • Modeling human brain development and disease in stem cell derived 3D organoid culture
  • Primary functions for “secondary” metabolites in microbial communities
Symposium 6: Logic of Signaling
Tuesday, Dec. 6, 9:45 a.m.
  • Anastasis, recovery from the brink of apoptotic cell death, in normal development and disease
  • Dissecting regulatory circuits: from cells to tissues
Symposium 7: Nuclear Organization
Wednesday, Dec. 7, 11:20 a.m.
  • The role of heterochromatin in a complex organism: Stabilizing the genome
  • Following single mRNAs from birth to death in living cells
Emerging Topic Symposium: Mitochondria and Cancer Cell Biology
Monday, Dec. 5, 7:20 p.m.
Jointly supported by the National Cancer Institute, NIH and the ASCB
  • Role of mitochondria in cancer cell adaptive responses and metastasis
  • Metabolic consequences of Ras-induced mitochondrial fission in pancreatic cancer
  • New frontiers in ER-mitochondrial dynamics
  • Role of SOD1 and the inter-membrane space in the mitochondrial UPR

ASCB 2016 minisymposia
 
All minisymposia sessions run concurrently on Sunday, Monday and Tuesday afternoon from 4:15 p.m. to 6:50 p.m. and on Wednesday morning from 8:30 a.m. to 11:05 a.m.
 
Sunday, Dec. 4
Minisymposium 1: Bacterial Mechanics, Development, Division, and Polymers
Minisymposium 2: Cell Cycle Regulation and Decisions
Minisymposium 3: Intermediate Filaments from Cytoplasm to Nucleus
Minisymposium 4: Membrane Traffic Control By Lipids, Cargos, and Motors
Minisymposium 5: Microtubule Dynamics
Minisymposium 6: Technological and Biological Frontiers in Signaling and Differentiation
 
Monday, Dec. 5
Minisymposium 7: Actin Dynamics
Minisymposium 8: Cell Biology of the Nucleus
Minisymposium 9: Chromosome Segregation Mechanisms
Minisymposium 10: Connecting Cells to Tissues
Minisymposium 11: Organelle Contact Sites and Biogenesis
Minisymposium 12: Post-transcriptional Gene Regulation
 
Tuesday, Dec. 6
Minisymposium 13: Cell Death and Genome Instability
Minisymposium 14: Cell Mechanics
Minisymposium 15: Cell Polarity and Morphogenesis
Minisymposium 16: Dark Matters in Signaling and Differentiation
Minisymposium 17: Genome Replication and Gene Regulation
Minisymposium 18: Quality Control and Organelle Trafficking
Minisymposium 19: Recent Developments in Autophagy and ESCRT Biology
 
Wednesday, Dec. 7
Minisymposium 20: Cell Division—Chromosome and Cytoskeletal Dynamics
Minisymposium 21: Cell Migration and Invasion
Minisymposium 22: Cell-Fate Determination in Signaling and Differentiation
Minisymposium 23: Membrane Traffic Control By Cytoskeletal and Molecular Machines
Minisymposium 24: Membrane-less Organelles
Minisymposium 25: Organ Development, Homeostasis and Disease
Minisymposium 26: Use Synthetic Biology to Measure and Manipulate Cell Biology
 
ASCB 2016 microsymposia
Two microsymposia sessions run concurrently on Sunday, Monday and Tuesday.
 
Sunday, Dec. 4, 11 a.m.-12:06 p.m.
Microsymposium 1: Autophagy/ESCRT Microsymposia
Microsymposium 2: Genome Replication, Gene Regulation, and Gene Editing
 
Sunday, Dec. 4, 12:25 p.m.-1:31 p.m.
Microsymposium 3: Cellular Interactions and Disease Microsymposia
Microsymposium 4: Organelles Microsymposia
 
Sunday, Dec. 4, 1:50 p.m.-2:56 p.m.
Microsymposium 5: Chromatin and Intranuclear Organization
Microsymposium 6: Cytoskeletal Molecular Dynamics
 
Monday, Dec. 5, 11 a.m.-12:06 p.m.
Microsymposium 7: Cell Adhesion and Migration
Microsymposium 8: Regulation of the Trafficking Machinery
 
Monday, Dec. 5, 12:25 p.m.-1:31 p.m.
Microsymposium 9: New Insights Into the Cell Division Mechanisms
Microsymposium 10: Spatial Organization of the Cell
 
Monday, Dec. 5, 1:50 p.m.-2:56 p.m.
Microsymposium 11: Development, Regeneration and Wound Healing
Microsymposium 12: Membrane Trafficking and Signaling
 
Tuesday, Dec. 6, 11 a.m.-12:06 p.m.
Microsymposium 13: Nuclear Structure, Function, and Movement
Microsymposium 14: Trafficking Dynamics and Imaging Microsymposia
 
Tuesday, Dec. 6, 12:25 p.m.-1:31 p.m.
Microsymposium 15: Cell Shape and Signaling
Microsymposium 16: Development and Invasion
 
Tuesday, Dec. 6, 1:50 p.m.-2:56 p.m.
Microsymposium 17: Cell Division in Development and Disease
Microsymposium 18: Signaling and Bioengineering
 
Exhibitor tech talks
 
Below is the majority of exhibitor tech talks just for Sunday alone during the ASCB annual meeting. There are also tech talks on Monday and Tuesday. For the full listing for all three days, visit www.ascb.org/2016meeting/techtalks.
 
A Biomimetic Cell Culture Platform for Enhancing Cell Biology Studies
NanoSurface Biomedical      
8:15 a.m.-8:30 a.m.
Experience level: Intermediate
Abstract: Cells maintained in vitro typically exhibit disordered cytoskeletal structures and random orientations. This disordered development can produce aberrant functional profiles and limit the utility of such in-vitro models in terms of providing predictive data relevant to mammalian cell function. Here we demonstrate that extracellular matrix-inspired substrate nanotopography drastically improves the structural and functional development of differentiated cells. Specifically, we show how our patented nanotopographic culture dishes can be utilized to study the effect of cell-nanotopography interactions on adhesion, signaling, polarity, migration and differentiation in the context of cancer biology, as well as regulation of epithelial wound healing, cardiovascular function and stem cell biology. This talk will cover a broad range of applications and discuss results achieved from analysis of over 20 adherent cell types.
 
Creation of an Industry Standard for the Sourcing of Human Samples
Scientist (formerly Assay Depot Inc.)
8:30 a.m.-8:45 a.m.
Experience level: Introductory
Abstract: The Scientist.com marketplace has changed how scientific research is sourced and managed. By simplifying access to experts and services, the marketplace has dramatically lowered barriers to scientific innovation and helped pioneer a new virtual approach to research. Scientist.com has also now teamed up with five large pharmaceutical companies to establish an industry standard for the sourcing of human biological samples. This rigorous compliance framework provides increased visibility, traceability and control while simplifying the user experience, saving time and money and improving access to innovative and routine human samples.
 
Normalization of Functional Cellular Metabolic Data using Cell Counting
BioTek Instruments Inc.
9:30 a.m.-10:30 a.m.
Experience level: Intermediate
Abstract: Changes in cellular metabolism underpin nearly all human disease. An integrated quantification of major metabolic pathways is possible using Seahorse XF analyzers from Agilent Technologies. Data normalization is often required to compare the metabolic poise of different samples, especially between cell types or treatment groups. Total cell number in each well is a widely accepted parameter for normalizing XF data; however, conventional methods for counting require additional procedures prone to error. In this Tech Talk, we will describe a new approach to normalization using the Cytation 5 Cell Imaging Multi-Mode Reader from BioTek Instruments Inc. Using in-situ assessment of cell number through digital microscopy, error due to sample preparation is decreased and accurate normalization can be applied to XF data.
 
Exploring the RANKL-RANK Axis in Bone Homeostasis and Cancer Metastasis
BioLegend
10:45 a.m.-11:45 a.m.
Experience level: Intermediate
Abstract: Receptor activator of nuclear factor-kappaB ligand, RANKL, is a member of the tumor necrosis factor family of cytokines. RANKL functions as a key factor for osteoclast differentiation, migration and activation through binding to its receptor RANK (receptor activator of NF-kappaB). This RANKL-RANK interaction is essential for bone formation. Besides maintaining bone homeostasis, it was recently found that RANKL also triggers cell migration of epithelial and melanoma cancer cells, that express the receptor RANK, to the bone. Here we present our portfolio, validation methods and data exploring this RANKL-RANK system in bone resorption and bone metastases using several assays such as cell differentiation, chemotaxis, ChIP and blocking capacity by target-ligand inhibition bioassays, among others. We’ll also explore RANKL-induced intra-cellular signaling pathways involved in these processes.
 
Simple workflows for cellular analyses from Cell Signaling Technology
Cell Signaling Technology
10:45 a.m.-11:45 a.m.
Experience level: Intermediate
Abstract: Antibody-based assays are often used to accurately detect and quantify protein expression and modification, providing information critical to our understanding of both normal and disease-related signaling. These assays may incorporate numerous antibodies and cell lines and/or tissues, allowing for multiplexed analysis of complex cellular signaling events and the simultaneous measurement of multiple endpoints within a single experiment. Here, we will review common antibody-based applications like IHC, ICC, HCS and flow cytometry. We will also demonstrate how highly validated fluorescently labeled antibodies and cellular dyes from Cell Signaling Technologies can be paired with the CellSimple Cell Analyzer to quickly and easily monitor biological processes, including cell health, viability, cell cycle, apoptosis and immune or other cellular signaling in multiplex whole cell assays or lysate-based bead assays.
 
High-throughput and Adaptive Feedback Microscopy
Carl Zeiss Microscopy  LLC
Noon-12:35 p.m.                               
Experience level: Advanced
Abstract: High-throughput microscopy of siRNA treated cells has become a standard tool for discovering genes with roles in specific biological processes. However, conducting high-throughput microscopy experiments is still challenging as it puts high demands on sample preparation, microscopy, image and data analysis. Moreover, further characterization of the “hit genes” often requires demanding microscopic assays that are difficult to perform even in medium throughput. This talk will outline the typical challenges occurring in high-throughput microscopy and discuss how dedicated microscope systems can help to tackle these challenges. In addition, it will describe how “adaptive feedback microscopy” allows scientists to perform highly complex microscopic assays in a fully automated manner, thereby enabling detailed and systematic further investigation of the identified “hit genes.”
 
Cytoskeletal Mechanics in the Beating Heart
Carl Zeiss Microscopy,LLC
12:35 p.m.-1:10 p.m.
Experience level: Advanced
Abstract: Microtubules have long been implicated in heartbeat regulation, yet their contribution to cardiac mechanics, and how it changes in disease, has remained obscure. One barrier to progress has been a lack of observation of microtubules in the living, beating myocyte. Recent advances utilizing Airyscan imaging have allowed us to capture microtubule behavior in contracting and stretching myocytes. Microtubules deform during the heartbeat, forming buckled sinusoids that resemble spring like elements and increase the mechanical resistance to myocyte contraction and stretch. We identify two key components regulating these microtubule mechanics: 1) post-translational “detyrosination” of cardiac microtubules and 2) desmin intermediate filaments. Additionally, we provide evidence that cytoskeletal resistance may limit cardiac function in human heart disease.
 
Dragonfly: A New Imaging Platform—Instant Confocal with Multi-Modal Imaging
Andor Technology
1 p.m.-1:45 p.m.
Experience level: Intermediate
Abstract: Dragonfly is a novel microscopy platform that in a single device includes instant confocal, widefield-deconvolution, simultaneous multi-color TIRFM and optical boost for 3D single-molecule localization microscopy. Driven by a new, dedicated software called Fusion to facilitate the multimodal imaging, the workflow covers image capture to real-time multidimensional rendering and deconvolution. Our new imaging platform and its many benefits include: 3D capture at least 10x faster than conventional confocal; patented optics delivering outstanding image quality, illumination throughput and uniformity with extended spectral range for deep large-sample imaging; single-molecule sensitivity for membrane studies and super-resolution; low-light imaging in non-confocal mode with GPU-accelerated deconvolution. Addressing subcellular imaging to whole sample biology, Dragonfly is perfect for core facilities or research projects requiring comprehensive imaging tools.
 
From 3D Light to 3D Electron Microscopy
Carl Zeiss Microscopy LLC
1:10 p.m.-1:45 p.m.
Experience level: Advanced
Abstract: The electron microscope (EM) is an invaluable tool for unraveling the structural details of cells and tissue. For the majority of questions the transmission electron microscope (TEM) is the standard to investigate resin embedded or cryo specimens. The scanning electron microscope (SEM) was mainly used to collect information on the topography of a specimen. However, the SEM emerged as a valuable imaging tool for traditional EM samples and thin sections, offering advantages over classical TEM approaches. These advantages include the opportunity to section a resin-embedded sample directly in the SEM, prepare large numbers of serial sections, image them automatically and include correlative light and electron microscopy easily into the workflow. The potential to complement, or even replace, the TEM in biological applications will be discussed.
 
Explore the Human Cell
Human Protein Atlas
2 p.m.-2:45 p.m.
Experience level: Introductory
Abstract: The subcellular distribution of 12,000 human proteins has been localized to 27 organelles and cellular structures using an antibody-based approach and high-resolution confocal microscopy. The high spatial resolution allows identification of novel protein components of all major organelles as well as fine cellular structures such as the cytokinetic bridge, nuclear bodies and rods and rings. Here we present a high-resolution proteome map of the human cell, the Cell Atlas. It is an image-based atlas detailing the subcellular distribution of the human proteome, as part of the Human Protein Atlas. It also includes chapters describing the organelle proteomes, multi-localizing proteins, cell cycle dependent proteins, and cell line transcriptomes.
 
Correlative and Statistical Localization Microscopy Using the Vutara 352
Bruker Corporation
2 p.m.-2:45 p.m.
Experience level: Introductory
Abstract: Super-resolution imaging, localization microscopy in particular, optically resolves spatial features within the cellular environment an order of magnitude below the classical diffraction limit. Due to the nature of the method, localization microscopy is often lacking in the contextual information of the overall cellular environment. Utilizing optical correlation microscopy through the Vutara 352 framework, it is possible to relate the large-scale cellular environment, obtained via swept-field confocal imaging, with more refined super-resolution localization data. Furthermore, its software offers numerous statistical analysis features to quantify the localization data into meaningful biological interpretations. These statistical features include spatial distribution tools such as Ripley’s K and pair correlation calculations, cluster, co-localization and resolution analysis, as well as live-cell tools such as mean-squared displacement calculations and particle tracking.
 
New transfection reagents for CRISPR editing and in vivo applications
Thermo Fisher Scientific Inc.
3 p.m.-4 p.m.
Experience level: Intermediate
Abstract: This talk will cover our latest transfection innovations for CRISPR editing and in-vivo applications. Topics included in the talk: Nucleic acid delivery solutions for hard-to-transfect and primary cells; delivery of genome editing tools, including cas9 protein; high-titer production solutions for lentivirus; and in-vivo delivery of RNAi and mRNA using Invitrogen Invivofectamine  3.0 reagent.
 
Creating an open source collection of GFP-tagged human iPSC lines to model cell organization and dynamics
Allen Institute for Cell Science
4:15 p.m.-5:15 p.m.
Experience level: Intermediate
Abstract: The Allen Institute for Cell Science (AICS) is creating a dynamic visual model of hiPSC organization using a suite of GFP-tagged hiPSC lines labeling 15 to 20 major organelles/molecular machines of the cell. We will present the CRISPR/Cas9 methodologies, workflows and QC metrics used to generate these endogenously tagged clonal cell lines and discuss our team and open science approach to create and share our tools and data. During this tech talk, we will focus on the following: 1) methods (CRISPR/Cas9) and workflow for creating the GFP-tagged lines, 2) assays and images for validation and QC, 3) list of structures and genes tagged, 4) access to cell lines and associated data and 5) community feedback for future line production.
 
Five Useful Teaching Examples Using NCBI BLAST
The National Center for Biotechnology Information
5:30 p.m.-6:30 p.m.
Experience level: Intermediate
Abstract: Sequence similarity search tools such as BLAST are fundamental to modern biology and are now taught to students in undergraduate biology classes or earlier. The NCBI has many standard demonstrations that we use to highlight the features of the BLAST. These examples are also useful for teaching biology principles and techniques including evolution, taxonomy, homology, multiple sequence alignment, phylogenetic trees, primer design and gene expression analysis. This workshop will provide you with examples using NCBI BLAST that explore these principles and techniques and are readily adaptable to your classrooms.
 
 
Code: E111632

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.